Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer

International Journal of Cancer

Volumn 74, Issue 4, 1997, Pages 383-389

  Erber, Ralf ^a   Klein, Wolfgang ^a   Andl, Thomas ^a   Enders, Christel ^a   Born, Antonio I ^b   Conradt, Christian ^b   Bartek, Jiri ^c   Bosch, Franz X ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BIOPSY; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; EPITHELIAL CELLS; EPITHELIUM; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MUTATION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RNA, MESSENGER; SURVIVAL RATE; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 0030757636     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R     Document Type: Article

References (21)

1. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer, 63, 611-615 (1995).
2. BUSCH, F.X., UDVARHELYI, N., VENTER, E., HEROLD MENDE, C., SCHUHMANN, A., MAIER, H., WEIDAUER, H. and BORN, A.I., Expression of the histone H3 gene in benign, semi-malignant and malignant lesions of the head and neck: a reliable proliferation marker. Europ. J. Cancer, 29a, 1454-1461 (1993).
3. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684 (1995).
4. DIGIUSEPPE, J.A., REDSTON, M.S., YEO, C.J., KERN, S.E. and HRUBAN, R.H., p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Amer. J. Pathol., 147, 884-888 (1995).
5. DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., MCARTHUR, M.J., MONTGOMERY, C.A., JR., BUTEL, J.S. and BRADLEY, A., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356, 215-221 (1992).
6. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
7. EL-DEIRY, W.S., TOKINO, T., WALDMAN, T., OLINER, J.D., VELCULESCU, V.E., BURRELL, M., HILL, D.E., HEALY, E., REES, J.L., HAMILTON, S.R., KINZLER, K.W. and VOGELSTEIN, B., Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919 (1995).
8. GU, Y., TURCK, C.W. and MORGAN, D.O., Inhibition of CDK2 activity in vivo by an associated 20K regulaton sub-unit. Nature (Lond.), 366, 707-710 (1993).
9. HALEVY, O., NOVITCH, B.G., SPICER, D.B., SKAPEK, S.X., RHEE, J., HANNON, G.J., BEACH, D. and LASSAR, A.B., Correlation of terminal cell-cycle arrest of skeletal muscle with induction of p21 by MsoD (see comments). Science, 267, 1018-1021 (1995).
10. HARPER, J.W., ADAMI, G.R., WEI, N., KEYOMAKSI, K. and ELLEDGE, S.J., The p21-Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases. Cell. 75, 805-816 (1993).
11. WAF1/CIP1 expression in the absence of p53. Oncogene, 9, 3397-3406 (1994).
12. WAF1/Cip1 in human brain tumors. Oncogene, 11, 2021-2028 (1995).
13. NODA, A., NING, Y., VENABLE, S.F., PEREIRA SMITH, O.M. and SMITH, J.R., Cloning of senescent-cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211, 90-98 (1994).
14. cip1 in muscle and other terminally differentiating cells (see comments). Science, 267, 1024-1027 (1995).
15. REHMAN, I., TAKATA, M., WU, Y.-Y. and REES, J.L., Genetic changes in actinic keratoses. Oncogene, 12, 2483-2490 (1996).
16. SERRANO, M., LEE, H.-W., CHIN, L., CORDON-CARDO, C., BEACH, D. and DEPINHO, R.A., Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85, 27-37 (1996).
17. SHIOHARA, M., EL-DEIRY, W.S., WADA, M., NAKAMAKI, T., TAKEUCHI, S., YANG, R., CHEN, D.L., VOGELSTEIN, B. and KOEFFLER, H.P., Absence of WAF1 mutations in a variety of human malignancies. Blood, 84, 3781- 3784 (1994).
18. STEINMAN, R.A., HOFFMAN, B., IRO, A., GUILLOUF, C., LIEBERMANN, D.A. and EL HOUSEINI, M.E., Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9, 3389-3396 (1994).
19. Ink4. Cancer Res., 54, 5816-5820 (1994).
20. WAGA, S., HANNON, G.J., BEACH, D. and STILLMAN, B.,The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA (see comments), Nature (Lond.), 369, 574-578 (1994).
21. XIONG, Y., HANNON, G.J., ZHANG, H., CASSO, D., KOBAYASHI, R. and BEACH, D., p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366, 701-714 (1993).